No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2243-2248

  Colao, Annamaria ^a   Marek, Josef ^b   Goth, Miklos I ^c   Caron, Philippe ^d   Kuhn, Jean Marc ^e   Minuto, Francesco M ^f   Weissman, Neil J ^g  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL MEDICAL CENTER   (Hungary)

^d SERVICE DE PNEUMOLOGIE   (France)

^e Institut National de la Santéet de la Recherche Médicale 0204   (France)

^f UNIVERSITY OF GENOA   (Italy)

^g WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; AORTA ANEURYSM; ARTICLE; ATRIOVENTRICULAR BLOCK; BILIARY COLIC; CHOLELITHIASIS; CLINICAL TRIAL; COLITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART VALVE REPLACEMENT; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MITRAL VALVE REGURGITATION; MORBIDITY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SINGLE BLIND PROCEDURE;

EID: 45149134343     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2199     Document Type: Article

References (17)

1. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102-152
2. Lie JT 1980 Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41-52
3. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G 2003 High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88:3196-3201
4. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ 2004 Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71-75
5. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM 2006 Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16:101-107
6. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ 2004 American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086-1119
7. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, Nihoyannopoulos P, Otto CM, Quinones MA, Rakowski H, Stewart WJ, Waggoner A, Weissman NJ 2003 Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777-802
8. Perry GJ, Helmcke F, Nanda NC, Byard C, Soto B 1987 Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol 9:952-959
9. Helmcke F, Nanda NC, Hsiung MC, Soto B, Adey CK, Goyal RG, Gatewood RP 1987 Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 75:175-183
10. Wright AD, Hill DM, Lowy C, Fraser TR 1970 Mortality in acromegaly. Q J Med 39:1-16
11. Orme SM, McNally RJ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83:2730-2734
12. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
13. Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
14. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W 2002 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99-104
15. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA 2004 The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 150: 473-480
16. Davies PH, Stewart SE, Lancranjan L, Sheppard MC, Stewart PM 1998 Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly. Clin Endocrinol (Oxf) 48:311-316
17. Freda PU 2002 Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018